About FAST

Welcome!

FAST was founded in 2008 with an urgent mission: to cure Angelman syndrome. Today, with operations in the United States, Australia, the UK, Canada, Italy, France, Spain and Latin America, our organization is the largest non-governmental funder of Angelman syndrome research, and we take this responsibility seriously. All financial gifts are invested wisely, and 88% of every dollar goes to support critical research! And, we don’t just write checks. FAST has set the research agenda for Angelman syndrome from bringing together a multidisciplinary team of more than two-dozen scientists from top research universities and pharmaceutical companies to join forces on a focused path to a cure to ensuring potential therapeutics do not languish in the laboratory. FAST formed the subsidiary, GeneTx Biotherapeutics, in order to develop an antisense oligonucleotide as a potential treatment for Angelman syndrome. FAST and GeneTx advanced this program from a proof of concept in the laboratory into clinical development. FAST was the first rare-disease patient organization to take this approach. GeneTx was the very first company to trial a potentially disease-modifying drug in this patient population.

Whereas most rare disease patient organizations would begin to relax and wait (and pray) for the results of their decisions, strategies and hard work to pay off, FAST is poised to work harder than ever to create meaningful change for the Angelman community. All of the advancements in Angelman syndrome, as well as FAST’s mission, would not be possible without the continued support of our community. All of us at FAST remain enormously grateful for your support and look forward to the many advancements that lie ahead as we #cureangelman.

Now is the time for action. FAST’s Roadmap to a Cure is bold, ambitious, and, with your help, achievable. Please join us by making a financial gift, spreading the word with friends and family members, and fundraising to help us cross the finish line. Our ultimate goal is to successfully complete this race – and no longer be necessary – by finding a cure.

The FAST Board
PO Box 40307
Austin, TX 78704

Phone: (630) 852-FAST
Fax: (630) 852-3270
Toll Free: (866) 783-0078
Email: info@cureangelman.org

FAST is the premiere Angelman syndrome patient advocacy organization, dedicated to curing AS through the funding of an aggressive research agenda. The foundation is committed to assisting individuals living with Angelman syndrome to realize their full potential and quality of life. Our goal is to bring practical treatment into current medical practice as quickly as possible. It is our hope that grants we fund will lead to additional research support from government agencies, other funding sources and organizations around the globe. FAST is served by two boards: the board of directors and the scientific advisory board. Together, we are working hard to bring practical treatment into current medical practice as quickly as possible.

We are 100 percent committed to accelerating treatments and a cure for Angelman syndrome (AS). The symptoms of AS have been under-addressed in the research community for far too long. Research aimed at identifying treatments for the motor dysfunction, seizures and behavioral characteristics of Angelman syndrome is one of FAST’s top priorities. FAST takes pride in investing in high-risk, high-reward research grants that have already produced positive and promising results. A cure for AS is now within reach but will require the expertise and collaboration of the best and brightest minds from a variety of fields in science and research.

In 2013, a true research collaboration and the infrastructure required to advance a cure for Angelman syndrome, was nonexistent. FAST addressed this challenge by creating the first-of-its-kind FIRE Initiative (FAST Integrative Research Environment), which funds more than two-dozen scientists from top universities to work collaboratively to identify, characterize and implement new therapeutics for the treatment and ultimate cure for Angelman syndrome. The FIRE Initiative is the most aggressive research program to date dedicated to finding a cure for AS.

For decades, small, non-profit disease research organizations like FAST have modeled their funding philosophies after the National Institutes of Health (NIH) where they budget their research dollars, put out a once-a-year call for applications, wait for scientists to come to them with ideas, select the most promising applications and hope they actually see results.  FAST is not at all interested in this slow, linear approach to funding research and instead adopted the innovative model of venture philanthropy, recruiting a stellar in-house team to work in partnership with leading scientists on ambitious, high-risk/high-reward study designs that will ensure promising therapeutics make it from the laboratory bench to the patient’s bedside as quickly as possible.

Adopting a business model where we have input and control over the direction of the research, FAST assembled an in-house team of experts in science, medicine, business management, finance, law, accounting and technology.  In addition to funding research grants, including over $360,000.00 in Postdoctoral Fellowships, FAST has also entered into contracted research on targeted projects with well defined milestones and deliverables.

Angelman Syndrome is currently one of the most promising fields of scientific research; relying solely on investigator-initiated research to identify and implement patient treatments is inefficient and short sighted.  Additionally, true collaboration of researchers working cooperatively is the only successful approach to treatment science.

In January 2011, FAST contracted research with Dr. Edwin Weeber to test four FDA approved compounds in our mouse model.  One of those compounds, Minocycline, showed promise in treating some of the symptoms of AS.  With additional funding and testing, Minocycline was identified as a candidate for human clinical trial.  FAST provided the funding for the trial in 2012 and we anticipate results to be published soon.

In May of 2013, FAST launched the most aggressive Angelman research initiative in history, bringing 24 researchers from 4 universities together in true collaboration to identify additional treatments and a cure for Angelman Syndrome.  The FAST Integrative Research Environment (FIRE) Initiative has already identified several possible treatment candidates for human clinical trial.  FAST will continue to either fund small, proof of concept trials that will better position the Angelman community for larger FDA funding and/or partner with pharmaceutical companies to bridge the so-called “Valley of Death” in translational research.

FAST has proven the success of our funding philosophy in a very short amount of time and with relatively little funding. It is not about how much you spend, but rather how you spend it.  FAST is funding smarter, faster science and with proper funding, a cure is now just within our reach.

FAST (Foundation for Angelman Syndrome Therapeutics) is an Internal Revenue Code Section 501(c)(3) nonprofit charity, exempt from federal taxation. Transparency is both a requirement and an obligation that is also vitally important to our members. 

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2021 Audited Financial Statements as well as a link to the FAST 2021 Federal Tax Return.  The FAST calendar year ended 2021 audited financials show total revenue of $6,327,514 and total expenses of $6,259,790. Additionally, there is $1,953,771 in non-operating losses recognized on FAST’s investment in GeneTx Biotherapeutics, LLC. Expenses of $6,259,790 include research funding in the amount of $3,910,364 and $1,607,858 in other program-related expenses. Fundraising expenses totaled $335,925, and general administrative expenses incurred by FAST in 2021 were $405,643.  $14,032,561 in net assets as well as $3,193,674 in grants payable were held at year-end, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see the FAST 2021 Audited Financials and FAST Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2020 Audited Financial Statements as well as a link to the FAST 2020 Federal Tax Return.  The FAST calendar year ended 2020 audited financials show total revenue of $4,167,109 and total expenses of $3,195,916. Additionally, there is $6,196,378 in non-operating gains recognized on FAST’s investment in GeneTx Biotherapeutics, LLC. Expenses of $3,195,916 include research funding in the amount of $2,401,977 and $421,618 in other program-related expenses. Fundraising expenses totaled $175,248, and general administrative expenses incurred by FAST in 2020 were $197,073.  $15,918,608 in net assets as well as $2,366,068 in grants payable were held at year-end, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. Notably, all compensation shown on Part VII of the FAST 990 is related to reportable compensation from our related organization, GeneTX Biotherapeutics, and properly classified in Column E. For detailed information, please see the FAST 2020 Audited Financials and  FAST Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2019 Audited Financial Statements as well as a link to the FAST 2019 Federal Tax Return.  The FAST calendar year ended 2019 audited financials show total revenue of $4,336,872 and total expenses of $5,128,132. Additionally, there is $1,968,564 in non-operating gains recognized on FAST’s investment in GeneTx Biotherapeutics, LLC. Expenses of $5,128,132 include research funding in the amount of $4,126,259 and $734,878 in other program-related expenses. Fundraising expenses totaled $183,057, and general administrative expenses incurred by FAST in 2019 were $83,938.  $8,751,037 in net assets as well as $3,197,375 in grants payable were held at year-end, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. Notably, all compensation shown on Part VII of the FAST 990 is related to reportable compensation from our related organization, GeneTX Biotherapeutics, and properly classified in Column E.   For detailed information, please see the FAST 2019 Audited Financials and  FAST Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2018 Audited Financial Statements as well as a link to the FAST 2018 Federal Tax Return.  The FAST calendar year ended 2018 audited financials show total revenue of $5,431,132 and total expenses of $3,104,807. Expenses of $3,104,807 include research funding in the amount of $2,260,991 and $414,253 in other program-related expenses.  Fundraising expenses totaled $203,437, and general administrative expenses incurred by FAST in 2018 were $226,126.  $7,573,733 in net assets as well as $1,174,132 in grants payable were held at year-end, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2018 Audited Financials and FAST Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2017 Audited Financial Statements as well as a link to the FAST 2017 Federal Tax Return.  The FAST calendar year ended 2017 audited financials show total revenue of $8,845,782 and total expenses of $5,739,913. Expenses of $5,739,913 include research funding in the amount of $5,218,272 and $232,586 in other program-related expenses.  Fundraising expenses totaled $191,049, and general administrative expenses incurred by FAST in 2017 were $98,006.  $5,247,408 in net assets as well as $2,462,895 in grants payable were held at year-end, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see  FAST 2017 Audited Financials and  FAST  Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2016 Audited Financial Statements as well as a link to the FAST 2016 Federal Tax Return.  The FAST calendar year ended 2016 audited financials show total revenue of $4,475,739 and total expenses of $3,529,159. Expenses of $3,529,159 include research funding in the amount of $3,039,187 and $63,381 in other program-related expenses.  Fundraising expenses totaled $313,486, and general administrative expenses incurred by FAST in 2016 were $113,105.  $2,141,539 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2016 Audited Financials and Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2015 Audited Financial Statements as well as a link to the FAST 2015 Federal Tax Return.  The FAST calendar year ended 2015 audited financials show total revenue of $1,121,173 and total expenses of $1,348,143. Expenses of $1,348,143 include research funding in the amount of $1,116,067 and $125,910 in other program-related expenses.  Fundraising expenses totaled $82,549, and general administrative expenses incurred by FAST in 2015 were $23,617.  $1,194,959 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2015 Audited Financials and Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2014 Audited Financial Statement as well as a link to the FAST 2014 Federal Tax Return.  The FAST calendar year ended 2014 audited financials show total revenue of $1,576,826 and total expenses of $1,256,386. Expenses of $1,256,386 include research funding in the amount of $1,042,667 and $112,293 in other program-related expenses.  Fundraising expenses totaled $78,121, and general administrative expenses incurred by FAST in 2014 were $23,305.  $1,571,929 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST.  For detailed information, please see FAST 2014 Audited Financials and Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2013 Audited Financial Statement as well as a link to the FAST 2013 Federal Tax Return. The FAST calendar year ended 2013 audited financials show total revenue of $913,798 and total expenses of $979,548. Expenses of $979,548 include research funding in the amount of $808,469 and $63,544 in other program-related expenses. Total general administrative expenses incurred by FAST in 2013 were $24,509. $1,101,489 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2013 Audited Financials and Federal Tax Return 2013.

The FAST calendar year ended 2012 audited financials show total revenue of $955,052 and total expenses of $391,600. Expenses of $391,600 include research funding in the amount of $253,890 and $58,550 in other program-related expenses.  Total general administrative expenses incurred by FAST in 2012 were $34,920, which included $17,476 of general administrative expenses and temporarily restricted funds of $17,444 for family travel expenses incurred in the Minocycline Clinical Trial.  $1,167,239 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For further details visit the following hyperlinks; Audited Financial Statements 2012 & Federal Tax Return 2012.

The FAST calendar year ended 2011 audited financials show total revenue of $639,525 and total expenses of $207,400. Expenses of $207,400 include research funding in the amount of $125,110 and other program-related expenses of $41,561.  Total general administrative expenses incurred by FAST in 2011 were $6,621.  $603,787 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For further details visit the following hyperlinks; Audited Financial Statements 2011 & Federal Tax Return 2011.

FAST (Foundation for Angelman Syndrome Therapeutics) is an Internal Revenue Code Section 501(c)(3), a nonprofit charity, exempt from federal taxation. Transparency is both a requirement and an obligation that is also vitally important to our members.

View FAST’s W9 form.

View our Conflict of Interest & Whistleblower Policy

"When the FAST community comes together with the brightest minds in the scientific field, positive, transformational change is happening."
Paula Evans
CEO of GeneTx Biotherapeutics
"Put the concept that “age matters” behind you and let human trials prove that ALL humans living with AS may very well benefit from gene replacement or gene altering therapies, regardless of age."
Dr. Allyson Berent
FAST Chief Science Officer
“Of all the childhood genetic neurologic disorders of the brain, Angelman syndrome may be the single best candidate for developing a definitive treatment (aka a cure).”
Dr. Arthur Beaudet
Professor
"It was the science that bought me into this, but it was the community that made me want to stay"
Dr. David Segal
Professor
“Research in Angelman syndrome offers the opportunity to unlock the ingenuity that we see every day interacting with individuals with AS. They can figure out any device and are avid problem solvers. We want to hear what they have to say. Their joy pushes us forward to figure out how we can improve their lives on a daily basis.”
Dr. Jessica Duis
Children Hospital Colorado
“FAST was such an integral part of my academic life. This outstanding foundation supported my work on Angelman syndrome for so many years. I am deeply humbled by this honor and by this opportunity to meaningfully contribute to FAST’s mission to cure Angelman syndrome.”
Dr. Jimmy El Hokayem
Biorasi, LLC

Leadership & Staff

FAST is served by two boards who work together to bring practical treatments into current medical practice as quickly as possible.

Allyson Berent.2 1

John Schlueter

Position: Chairperson

John is the owner of Frontline Commercial Real Estate, LLC, where he develops, acquires, finances, and leases retail and industrial commercial real estate. Concurrently, his manufacturing business, Keder Solutions LLC, designs, manufactures, and distributes textile reinforcement products internationally. Prior to this, John led his family business to become the largest manufacturer and installer of temporary structures. A few notable clients include Walt Disney World, NFL/Super Bowl, IMG/New York Fashion Week, and the 2010 Vancouver Winter Olympic Games. John’s daughter Grace has Angelman syndrome.

Allyson Berent.2 1 john and grace crop out sign

John Schlueter

Chairperson
Allyson Berent.2

Allyson Berent‑Weisse

Position: Chief Science Officer

Allyson is a veterinarian in New York City. She received a bachelor’s degree and doctor of veterinary medicine degree from Cornell University. She is a member of the American College of Veterinary Internal Medicine and is a specialist in internal medicine and interventional radiology/interventional endoscopy. She is a director of interventional endoscopy at one of the largest specialty animal hospitals in the world. She has spent the last 10 years performing clinical research and designing various clinical trials to develop and evaluate novel therapeutics and medical devices in dogs and cats. Allyson has three children. Her daughter Quincy has Angelman syndrome.

Allyson Berent.2 A Berent and Quincy

Allyson Berent‑Weisse

Chief Science Officer
kelly

Kelly David

Position: Co-Vice Chair

Kelly David, M.A., CCC-SLP, received her BS in Biology and Master of Arts degree in Communication Sciences and Disorders from the University of Central Florida. She is a member of the American Speech-Language Hearing Association (ASHA) and licensed in the state of Florida. She has served populations from pediatric to geriatric, with developmental and/or acquired disorders. She currently works as a clinical instructor at the University of Central Florida’s Communication Disorders Clinic. She has experience speaking at both the state and national level on topics related to self-advocacy, traumatic brain injury, and incorporating the client/caregiver voice in therapy approaches. Her most important role, however, is as mother to Colin and Madeline. Her son, Colin, lives with Angelman syndrome.

kelly Kelly Colin v2

Kelly David

Co-Vice Chair
K Dixon profile pic

Kristy Dixon

Position: Co-Vice Chair & Treasurer

Kristy is an international program manager for Lockheed Martin in Orlando, Fla. Kristy has worked at Lockheed Martin since 2002 in various customer-facing positions within engineering, business development and program management. Her strengths in building personal customer relationships, developing and executing win strategies, and leading cross-functional teams has enabled her to find solutions that meet customer needs resulting in the award of significant customer funds. Kristy earned a Bachelor of Science degree in computer and information sciences from the University of Florida and a Master of Science degree in computer science from the Florida Institute of Technology. Kristy has a daughter, Grace, with Angelman syndrome.

K Dixon profile pic K Dixon and Gracejpg

Kristy Dixon

Co-Vice Chair & Treasurer
Amelia Beatty 1

Amelia Beatty

Position: Secretary

Amelia Beatty received her undergraduate degree from Wellesley College and her Master of Arts degree at Sotheby’s Institute of Art London. Amelia has lived and worked in San Francisco, Boston, London, Los Angeles, Shanghai, China; Brazzaville, Congo and Algiers, Algeria. Her diverse jobs have included catering, managing an art gallery, managing security for diplomats, and working with the U.S. Department of Defense. Amelia and her husband have three sons. Their middle son has a congenital heart defect and apraxia of speech. Their youngest son, Orion, has Angelman syndrome. Becoming fluent in French while living abroad, Amelia and her husband decided to have a bilingual family, and have largely succeeded in spite of the communication challenges with two of their children. Amelia and her family live in Amman, Jordan.

Amelia Beatty 1 D92069C4 7874 4F58 BA53 84681B81274C

Amelia Beatty

Secretary
RJ1

Ryan Jacob

Position: Executive Director

Ryan is the chief executive officer for CAE, a global software- and information-driven trading firm addressing the semiconductor market. Additionally, Ryan is a chairman of Jacob Family Holdings and serves as a director for numerous private companies. Prior to CAE, Ryan worked in venture capital and private equity at Summit Partners, Endeavour Capital and Celerity Partners. He’s a graduate of the University of California, Los Angeles. Throughout his career, Ryan has been focused on investing in and helping to grow private companies and conveying those beneficial practices to non-profit organizations. Ryan’s son Grayson has Angelman syndrome.

RJ1 RJ2

Ryan Jacob

Executive Director
Roy Azout

Roy Azout

Position: Director

Roy received a Bachelor of Science degree in economics from The Wharton School at University of Pennsylvania, where he graduated magna cum laude. He is owner and corporate manager at Lafayette S.A.S., a vertically integrated, state-of-the-art, textile manufacturing and distribution company, which was founded in 1942 and has customers in 24 countries around the world. Roy grew up and lives in Bogota, Colombia. Roy has three children, his daughter Michelle has Angelman syndrome.

Roy Azout roy azout daughter

Roy Azout

Director
Meagan Cross

Meagan Cross

Position: Director

Meagan has a background in information science operates a geographic information science consultancy with experience in data development, management, analysis and presentation. Meagan also runs a business in Far North Queensland Australia with her husband, Rohan. In addition, Meagan is chairperson of sister organization FAST-Australia and the founder of the Global Angelman Syndrome Registry. Meagan has two children. Her daughter Molly has Angelman syndrome.

Meagan Cross Meagan and Molly

Meagan Cross

Director
Mike Hanrahan

Mike Hanrahan

Position: Director

Mike is the Chairman of Sustain.Life, a sustainability SaaS platform and also CEO of 4Sided Venture Studios.  Prior to that Mike established and ran Walmart’s artificial intelligence computer vision group while also serving on the board of GeneTx Biotherapeutics, where he had the pleasure of working with the incredible team that shepherded GTX-102 to in human trials and eventual sale to Ultragenyx.

Mike and his wife Jo are parents to 4 amazing children, including Tom who is their deletion positive Angelman child and light of their life.  Mike hails from Ireland, but has lived in London for 14 years before settling in New Jersey in 2010.

Mike Hanrahan Mike Hanrahan 2

Mike Hanrahan

Director
Lauren Hoffer

Lauren Hoffer

Position: Director

Lauren is an attorney for Dell Technologies. Lauren handles high stakes intellectual property litigation, licensing, intellectual property policy, and various legal matters for the company. Lauren also serves as a Committee Chair for Dell legal’s Diversity, Equity & Inclusion efforts and is an active member of Dell’s Innovation and Assistive Technology Committee. Prior to joining Dell, Lauren practiced law at Morgan, Lewis & Bockius and Jones Day law firms where she focused on commercial and IP litigation. Lauren earned her undergraduate degree from the University of Texas at Austin and her law degree from Georgetown University Law Center.

Lauren’s work for FAST includes policy issues, grant contracts, and future planning to help ensure FAST accomplishes its mission that all living with Angelman syndrome receive a meaningful therapeutic. Lauren and her family continue to fundraise for FAST. Lauren has been an active community leader and volunteer throughout her life, serving on boards and committee for various civic and charitable organizations. Lauren lives in Austin, Texas with her husband, Greg, and their two sons, Charlie and Ben, who lives with Angelman syndrome.

Lauren Hoffer lauren and ben

Lauren Hoffer

Director
ben oconnor 1 1

Ben O’Connor

Position: Director

Ben O’Connor, director, is a litigation and trial attorney for Hilliard Martinez Gonzales LLP in Chicago, where he focuses on personal injury and mass tort cases. He previously worked for Kirkland & Ellis LLP in Chicago, with broad practices in commercial litigation, white-collar criminal defense, criminal postconviction relief, and government and internal investigations. He received his bachelor’s degree from the University of Notre Dame, a master’s degree from Saint Louis University, and a Juris Doctor from The John Marshall Law School in Chicago. Prior to joining Kirkland & Ellis, Ben served as a law clerk for the Hon. William J. Bauer on the United States Court of Appeals for the Seventh Circuit in Chicago. Before becoming an attorney, Ben was a high school theology teacher and football coach at Loyola Academy in Wilmette, Illinois. Ben lives outside of Chicago with his wife, Elizabeth, and their two children. His son, Ryan, has Angelman Syndrome.

ben oconnor 1 1 ben o connor

Ben O’Connor

Director
nora

Nora Xu

Position: Director

Nora is the Group Marketing Manager for Microsoft. In her role at Microsoft, Nora leads a team focused on integrated marketing programs and initiatives to establish a unified message for Microsoft Advertising. Nora has over 10 years of combined experience at Microsoft. Prior to her current role at Microsoft, Nora worked as a product marketing manager for well-known mobile and web application brands. She is a graduate of the University of Waterloo in Canada. Nora brings 20 years of extensive marketing experience with a background in creative marketing, storytelling, strategic partnerships and community engagement to the FAST Board of Directors. Nora’s daughter, Arbor, has Angelman syndrome.

nora nora xu fam

Nora Xu

Director
paula2

Paula M. Evans

Position: Founder

Paula earned a Bachelor of Science degree in architectural technology from the New York Institute of Technology. Her career focused on residential and commercial property management in both Manhattan and Chicago. Paula oversaw the management and title transfer of multimillion-dollar properties, and handled all property negotiations, purchasing, construction/renovation projects and staff supervision. Her portfolio contained some of the highest-profile buildings and entities in the above-mentioned cities. Paula has two children. Her daughter, Ainsley, has Angelman syndrome.

paula2 paula and ainsley

Paula M. Evans

Founder
Alana

Alana Newhouse

Position: President

Alana Newhouse is the editor-in-chief of Tablet Magazine, which she founded in 2009. Originally conceived as a platform for Jewish news and ideas on the web, it has grown into an address for reporting and arguments regularly cited by the New York Times, the Washington Post, The New Yorker, and others—read by readers of all backgrounds, from around the world. Before journalism, Alana worked for legendary New York City political guru David Garth. She is a graduate of Barnard College and Columbia University’s School of Journalism. She lives in New York City with her husband and family, including her son Elijah, who has Angelman syndrome.

Email: alana.newhouse@cureangelman.org

Alana

Alana Newhouse

President
RKFHS6

Ryan Fischer

Position: Chief Operating Officer

Ryan joins the team as FAST’s Chief Operating Officer. Ryan will work in collaboration with FAST’s President to establish, direct, and achieve the organization’s short and long-term strategic goals and objectives across all operational areas, including general administration, programs, grants, and external relations. He will maintain and build effective relationships with key stakeholders, including Congress, regulators, pharmaceutical companies, other foundation leaders, and the broader rare disease advocacy community. Prior to joining FAST, Ryan served as Chief Advocacy Officer for Parent Project Muscular Dystrophy (PPMD). Ryan held various roles within PPMD over 18 years helping to grow the organization into one of the leading rare diseases advocacy nonprofits globally.

Email: ryan.fischer@cureangelman.org

RKFHS6

Ryan Fischer

Chief Operating Officer
Kena head shot 2019

Kena Richert

Position: Chief Financial Officer

Kena Richert is a founding board member of FAST. In March 2020, Kena joined FAST’s staff as the Chief Financial Officer. Previously, Kena provided audit services to Fortune 500 companies in the assurance practice at PricewaterhouseCoopers LLP. Kena is a member of the American Institute of Certified Public Accountants and the Texas State Board of Public Accountancy. She is a Chartered Global Management Accountant. Kena has three children; her oldest daughter, Ashley, lives with Angelman syndrome.

Email: kena.richert@cureangelman.org

Kena head shot 2019 K. Richert and Ashley

Kena Richert

Chief Financial Officer
Jena 3

Jena Berndt

Position: Community Advocate Leader

As community advocate leader at FAST, Jena is responsible for driving awareness of initiatives, programs, and events, and developing new community programs. As someone passionate about science and communicating FAST-funded research initiatives, she plays an instrumental role in sharing information, education, and support with others. Jena and her husband, Sean, live in Fall River, Wisconsin. They have five children; their daughter, Payslie, lives with Angelman syndrome.

Email: jena.berndt@cureangelman.org

Jena 3

Jena Berndt

Community Advocate Leader
Jennifer Panagoulias Headshot

Jennifer Panagoulias

Position: Head of Regulatory and Policy, Co-director of ABOM*

Jennifer is the Head of Regulatory and Policy for FAST and Co-director of ABOM. She has worked in drug development for over 20 years, primarily focused on advancing global development programs for the treatment of rare neurological diseases. Her background and experience working with global regulatory agencies to support diverse drug and biological therapy development programs in both the development and post-marketing strategies will greatly benefit the FAST community. Jennifer resides in Danvers, MA. She has a niece, Samantha who lives with Angelman syndrome.

*Volunteer Role

Jennifer Panagoulias Headshot

Jennifer Panagoulias

Head of Regulatory and Policy, Co-director of ABOM*
Laura

Laura Foglyano

Position: Meetings & Operations Manager

Laura joins the staff as the Meetings & Operations Manager. Prior to FAST, she spent 17 years working in Philanthropy and Marketing at Cleveland Clinic. She planned events ranging from large gala fundraisers and hospital grand openings to a Presidential Debate. Laura’s background in healthcare marketing and fundraising will help FAST stay organized, efficient and focused on its mission. She resides in Shaker Heights, OH with her husband, two children, and rescue dog.

Email: laura.foglyano@cureangelman.org

Laura

Laura Foglyano

Meetings & Operations Manager
Meghan1

Meghan Edberg M.Ed.

Position: Director of Community Engagement

Meghan joins FAST as the Director of Community Engagement. Prior to FAST, she spent 16 years in a variety of roles working with diverse populations building a strong skillset in business and counseling. She will support how the FAST engages with the community on a strategic, operational, and personal level. She resides in Rosemount, MN with her husband and two children. Her son William lives with Angelman syndrome.

Email: meghan.edberg@cureangelman.org

Meghan1 Meghan2

Meghan Edberg M.Ed.

Director of Community Engagement
Nycole 1

Nycole Copping, PhD

Position: Science Director

Nycole joins the team as the Science Director. She will focus on grant management and engagement with the science community in experimental design and planning. She will work in tandem with our Chief Science Officer to manage our rapidly and robustly expanding translational research projects. Prior to joining the team, Nycole spent 10 years working with preclinical models of rare neurodevelopmental disorders at UC-Davis in Dr. Jill Silverman’s laboratory. She and her husband reside in Sacramento, CA with their two corgi dogs, Rodney and Roland.

Email: nycole.copping@cureangelman.org

Nycole 1

Nycole Copping, PhD

Science Director
placeholder

Amber Bridgers

Position: Staff Accountant

Amber Bridgers is a Staff Accountant at FAST. Amber supports the Chief Financial Officer with the day-to-day functions. She brings nearly two decades of experience in business administration and accounting. Before joining FAST, Amber worked as a staff accountant at Service Tech Inc. and Texas Sun and Shade. She received her degree in Business Administration and Management from Austin Business College.

Email: amber@cureangelman.org

placeholder

Amber Bridgers

Staff Accountant
albert keung featured

Albert Keung
Ph.D.

Position: Assistant Professor of Chemical and Biomolecular Engineering

NC State University
View Website
Speciality: stem cell models and molecular tools to understand epigenetic mechanisms of the human brain

albert keung featured

Albert Keung
Ph.D.

Assistant Professor of Chemical and Biomolecular Engineering
Anne Anderson

Anne Anderson
M.D.

Position: Associate Professor

Departments of Pediatrics and Neurology and Division of Neuroscience Baylor College of Medicine Houston, TX
Visit Website
Specialties: Clinical Neurophysiology, Pediatric Neurology

Anne Anderson

Anne Anderson
M.D.

Associate Professor
Art Beaudet

Art Beaudet
M.D.

Position: Founder and CEO of Luna Genetics

Texas Children’s Hospital
View Website
Specialty: Genetics

Art Beaudet

Art Beaudet
M.D.

Founder and CEO of Luna Genetics
Ashley Winslow

Ashley Winslow
PH.D.

Position: Distinguished Scientist

Chief Science Officer, Odylia Therapeutics

Specialty:  Gene Therapy and Clinical Development

Ashley Winslow

Ashley Winslow
PH.D.

Distinguished Scientist
barbara bailus

Barbara Bailus Ph.D.

Position: Scientific Advisory Board Chair

Assistant Professor of Genetics
Institution: Keck Graduate Institute, Claremont Colleges

Website: https://www.kgi.edu/people/barbara-bailus/

Specialty: Genetic Engineering, Protein Delivery

Dr. Barbara Bailus is an Assistant Professor of Genetics at The Keck Graduate Institute, of the Claremont Colleges. She did her doctoral research at University of California, Davis in the Segal Laboratory developing a gene therapy based on artificial transcription factors for the treatment of Angelman Syndrome.  Her postdoctoral research in the Ellerby Lab at The Buck Institute for Research on Aging, focused on potential therapies for Huntington’s disease including small molecules and gene editing proteins.  For the past several years Dr. Bailus has been honored to serve as a scientific advisor and communications reporter for The Foundation for Angelman Syndrome Therapeutics (FAST).  Dr. Bailus has a passion for teaching the next generation of scientists and communicating exciting scientific advances to the public.  When not in the lab or classroom she enjoys being outside, traveling, riding horses, and painting.

barbara bailus

Barbara Bailus Ph.D.

Scientific Advisory Board Chair
BrettAbrahams

Brett Abrahams, Ph.D.

Position: Board Member

Dr. Abrahams is a neuroscientist, geneticist, and drug hunter with experience developing therapeutics and building startups. He is the founder and President of Heppinn Biosciences, a consultancy practice launched to support venture investors, foundations, and biotech companies diligence opportunities, develop drugs, and start biotech companies. He’s also an Advisory Board Member for Autism Speaks, CureShank (Phelan McDermid Syndrome), and Accelerator Life Science Partners.

Prior to launching Heppinn, Dr. Abrahams served as Executive Vice President of Research and Development of Magnolia Neurosciences. The company was founded to develop novel therapeutics for neurodegenerative disorders and built out around investment from Arch, Pfizer Ventures, Eli Lilly, and others. Dr. Abrahams joined Magnolia from Ovid Therapeutics, leaving as Senior Director and Head of Pre-Clinical Biology. While there, he helped to move multiple autism and epilepsy-related assets into the clinic and was part of the team that showed clinical benefit of Gaboxadol (OV101) in Angelman Syndrome and Soticlestat (TAK935) in Dravet Syndrome.

Prior to this, Dr. Abrahams was full-time faculty with an independent laboratory at the Albert Einstein College of Medicine, where he retains an adjunct appointment. His lab applied genomic strategies to identify novel disease genes and then studied the molecular, cellular, and behavioral consequences of identified variants in disease models and patients. He was also closely involved in the development of the Simons Foundation’s SFARI Gene, an autism-focused knowledge base for researchers and clinicians. His research, published in numerous high impact journals including Cell, New England Journal of Medicine, Nature, and Science Translational Medicine, has been cited more than 10,000 times.

Following a PhD in Neuroscience at the University of British Columbia / CMMT with Dr. Elizabeth Simpson, Dr. Abrahams did a Post-doctoral fellowship in the Dept. of Neurology at UCLA with Dr. Daniel Geschwind.

BrettAbrahams

Brett Abrahams, Ph.D.

Board Member
Bryce Reeve

Bryce Reeve
Ph.D.

Position: Professor in Population Health Sciences

Duke University
View Website
Speciality: Health Measurement and Health Services Research

Bryce Reeve

Bryce Reeve
Ph.D.

Professor in Population Health Sciences
Cesar.Ochoa Lubinoff.2020

Cesar Ochoa-Lubinoff
Ph.D.

Position: Board Member

Speciality: Pediatric Psychology, Pediatric Psychiatry, Developmental Behavior

Rush University
Chicago, IL

Website: https://doctors.rush.edu/details/1693/cesar-ochoa-lubinoff-developmental_behavioral_pediatrics-chicago

Cesar.Ochoa Lubinoff.2020

Cesar Ochoa-Lubinoff
Ph.D.

Board Member
Segal David

David Segal Ph.D.

Position: Professor
 

UC Davis Genome Center, Department of Biochemistry and Molecular Medicine, Pharmacology,
MIND Institute,
UC Davis School of Medicine
Visit Website
Specialty: Genomic therapeutics

Segal David

David Segal Ph.D.

Professor
 
Dr. Liz Berry Kravis

Elizabeth Berry-Kravis
Ph.D.

Position: Professor

Specialty: Pediatric Neurology

Rush University
Chicago, IL

Website: https://doctors.rush.edu/details/1323

Dr. Liz Berry Kravis

Elizabeth Berry-Kravis
Ph.D.

Professor
Load more  

Derek Matheson

Derek Matheson Ph.D.

Position: Council Member

Director of hospitalists
Institution: Jane Phillips Medical Center

Dr. Derek Matheson is a graduate of Oklahoma State University College of Osteopathic Medicine and has over two decades of internal medicine experience. Dr. Matheson’s youngest child, Remi, was diagnosed with Angelman syndrome in June 2018.

Derek Matheson Derek Matheson 2

Derek Matheson Ph.D.

Council Member
Derrick Webb1

Derrick Webb

Position: Council Member

Derrick Webb is the manager of human resources and labor relations for Cleveland–Cliffs. For over 15 years, Derrick has worked in labor relations and human resources for the steel manufacturing industry. Derrick and his wife, Johnna, live in Owensboro, Kentucky with their three kids. Their middle daughter, Harper, lives with Angelman syndrome.

Derrick Webb1 Derrick Webb2

Derrick Webb

Council Member
Easton1

Easton Bryant

Position: Council Member

Easton Bryant, PharmaD, is the owner of an independent pharmacy, North Century Pharmacy, in Columbia, Kentucky. Bryant’s pharmacy offers a full line of innovative services including pharmacogenomic testing. He is passionate about helping others make educated and informed decisions regarding health-related issues. His oldest daughter, Izzie Mae, lives with Angelman syndrome.

Easton1 Easton2

Easton Bryant

Council Member
Johnna1

Johnna Webb

Position: Council Member

Johnna Webb has over 15 years of accounting and finance experience in both public and private accounting. Johnna was recently the Controller of a local hospital prior to moving to Owensboro and currently works in the hospital financial setting. She was part of the first class for Kentucky’s Partners in Policy Making. She resides with her husband, Derrick, and their three children. Their daughter, Harper, lives with Angelman Syndrome.

Johnna1 Johnna2

Johnna Webb

Council Member
Dr. Joe D Orazio

Joe D’Orazio Ph.D.

Position: Council Member

Assistant Professor of Emergency Medicine
Institution: Lewis Katz School of Medicine at Temple University

Dr. D’Orazio serves as a medical toxicology consultant for the Poison Control Center at the Children’s Hospital of Philadelphia. He brings extensive experience in emergency medicine, medical toxicology, addiction medicine and has been involved in various clinical trials. His son, Gabriel, has Angelman syndrome.

Dr. Joe D Orazio Joe D Orazio

Joe D’Orazio Ph.D.

Council Member
Karly1

Karly Werner

Position: Council Member

Karly Baraga Werner is an experienced attorney and government relations professional. She has worked in the telecommunications industry for almost two decades, representing companies in front of federal, state and local regulators and governments, in advocating for and assisting with strategic growth initiatives. She currently works for Comcast in Government Affairs, covering MN, WI, MO and KS. Karly is a graduate of Georgetown Law School and a participant in the Humphrey School of Public Policy’s Policy Fellow program. Karly keeps busy with her three kids’ many sports and activities – Margot (13), William (12) and Louis (6) – and tries to stay sane by practicing yoga and reading novels.

Karly1 Karly2

Karly Werner

Council Member
Laura1

Laura Sargent, APRN, PNP

Position: Council Member

Laura Sargent, APRN, PNP, is a pediatric nurse practitioner at Children’s Mercy in Kansas City, Missouri. She manages the developmental, nutritional, respiratory and other generalized healthcare needs of children born prematurely and with complex medical conditions. Laura and her husband, Patrick, have three children. Their daughter, Maddie, lives with Angelman syndrome.

Laura1 Laura2

Laura Sargent, APRN, PNP

Council Member
sue

Sue Edberg

Position: Council Member

Sue Edberg, MBA, is a Minnesota native and the grandmother of William, who has Angelman syndrome. After her career breaking barriers in the nonprofit and the corporate worlds, she now focuses on seeing it through that her grandson and all the other angels get a cure for Angelman syndrome. She brings a strong skill set in fundraising and advocacy to help support FAST’s mission. She lives in West St. Paul, MN with her husband, Jim. They have two sons, and four grandchildren.

sue sue2

Sue Edberg

Council Member
tami1

Tami Hicks

Position: Council Member

Tami Hicks is mom to Ethan, age 22, who is living with Angelman Syndrome. Tami has been in public education for 17 years with 9.5 of those years in administration.  Tami is a Doctoral candidate at Purdue University researching educational leadership and policy.  She is now President / CEO of the Boys & Girls Clubs of Elkhart County in northern Indiana. Tami and her husband, Bryan Wodtkey, have been married almost six years in June of 2023.

tami1 tami2

Tami Hicks

Council Member
2019 Terry Jo headshot orange

Terry Jo V. Bichell Ph.D.

Position: Council Member

Dr. Terry Jo V. Bichell has a Ph.D. in Neuroscience. She is the founder and director of COMBINEDBrain, which is devoted to speeding the path to clinical treatments for people with severe rare genetic non-verbal neurodevelopmental disorders. While working as a documentary filmmaker, Dr. Bichell’s youngest child, Lou, was diagnosed with Angelman syndrome. She quickly switched focus to help move bench science into the first clinical trials for Angelman syndrome. Dr. Bichell is a highly-published, experienced researcher with a history of working in neuroscience and women’s health.

2019 Terry Jo headshot orange TJ and Lou

Terry Jo V. Bichell Ph.D.

Council Member
Todd1

Todd Werner

Position: Council Member

Todd Werner, co-founding attorney of Avantech Law, has joined the FAST Advisory Council (FAC) as council leader. Werner is an intellectual property attorney bringing extensive experience from the pharmaceutical industry. His son, Louie, lives with Angelman syndrome.

Todd1 Todd2

Todd Werner

Council Member
Jim Daley cropped sml

Jim Daley Ph.D.

Position: Council Member

Research Assistant Professor
Institution: University of Texas Health Science Center, San Antonio

Dr. Jim Daley attended the University of Michigan for his Ph.D. in Cellular and Molecular Biology, and performed postdoctoral work at the University of Montreal and Yale University. He studies DNA damage, genome instability and cancer. Dr. Daley has a younger sister, Jennie, with Angelman syndrome.

Jim Daley cropped sml Daley

Jim Daley Ph.D.

Council Member

Colin Farrell on FAST​

Colin Farrell speaks about Angelman syndrome, the Foundation for Angelman Syndrome Therapeutics and the FAST Gala.

video thumbnails colin
Play Video

FAST is Global

In an age where Angelman syndrome therapeutics are being developed on a global scale, FAST is working to make sure communities across the world are organized and prepared to participate in studies for potential therapeutics. FAST is committed to bringing the Angelman syndrome community the most current updates on research and clinical trials. Hear from each country’s FAST chairperson in this video and learn more about how they are all advancing Angelman syndrome research and clinical trials. 

FAST has affiliates in Australia, Canada, France, Italy, Latin America (Argentina, Chile, Colombia), Spain and the UK.

Australia
canada3
france3
italy3
FASTSpain2
uk3
LatAm

A FAST History

1997
August 2008
December 2008
October 2010
September 2011
December 2011
April 16, 2012
December 2012
December 2, 2012
June 2013
February 15, 2014
April 2015
July 2015
November 2015
March 7, 2016
July 2016
September 2016
October 2016
February 2018
March 2018
July 2018
October 2019
February 2020
May 2020
May 2020
May 2020
August 2020
Dr.ArtBeaudet
Dr. Art Beaudet discovers UBE3A is the causative gene for Angelman syndrome.
Watch
Picture1
FAST Launches
Paula's Story
1st Gala NewsLetter February2009.2
FAST Hosts First Gala
Learn More
FAST Australia is Launched
Learn More
FAST
Vivint Gives Back-win $250,000
Watch
RKP 101
2011 FAST Gala
526197 10150807243666277 414134024 n
1st FAST funded clinical trial-Minocycline with Dr. Weeber
Learn More
The FIRE Team
FIRE (FAST Integrative Research Environment) is launched
Learn More
Screen Shot 2020 11 11 at 5.16.49 PM
1st Annual Scientific Round Table (Science Summit)
Learn More
CFC 2ApprovedCharity 2C Blue
FAST is included on the Combined Federal Campaign (CFC) Charity List.
Learn More
1st Annual International Angelman Day
Learn More
jeremy levin ovid
Ovid Therapeutic Launches first sponsored clinical trial for AS
Learn More
Ed Weeber Agilis Announcement
Dr. Edwin Weeber and Agilis Biotherapeutics enter into worldwide licensing agreement for Angelman syndrome gene therapy
Learn More
Agilis Nov 2015
Agilis Biotherapeutics announces FDA orphan drug designation for AGIL-AS for treatment of AS
Learn More
boimarkers2 scaled
The Angelman Biomarkers and Outcome Measures Consortium is created
Learn More
stem cells IRC signage700
FAST Funded Research leads to $1.1 million grant
Learn More
FAST Receives $5.8 million grant from Marnier-Lapostolle Foundation
Learn More
FASTUK 3 scaled
FAST UK is formed
Learn More
GeneTx.Logo Transparent high res
FAST announces the launch of GeneTx Biotherapeutics, a subsidiary of FAST
Learn More
GeneTx Biotherapeutics receives FDA orphan-drug designation for Angelman syndrome treatment
Learn More
Zev Noah FAST Canada
FAST Canada is formed
Learn More
FAST Italy with Colin
FAST Italy is formed
Learn More
GTX102 Clinical Study
GeneTx Announces GTX-102 is approved for clinical study.
Learn More
Charity Navigator 4StarRect
FAST rated a 4-star charity by Charity Navigator
Learn More
Segal Lab group outdoor
FAST funds UC Davis team to build a lab devoted to Angelman syndrome (AS) research
Learn More
Bienvenue FAST France2
Bienvenue FAST France
Learn More
Partnership with HealX.2
Healx-FAST Collaboration
Learn More

Resources

can3.1.21
As diverse as our Angelman community is, we are all united in one goal: a better future for our children. FAST is committed to bringing life-changing treatments to all individuals with Angelman syndrome, but we need your help!
Start Fundraising
Start Fundraising
Start Fundraising
Start Fundraising
can3.1.21
As diverse as our Angelman community is, we are all united in one goal: a better future for our children. FAST is committed to bringing life-changing treatments to all individuals with Angelman syndrome, but we need your help!
Start Fundraising
Start Fundraising
Start Fundraising
Start Fundraising

Find the latest on what is happening with the FAST organization and its community.

Foundation Updates
Foundation Updates

FAST (Foundation for Angelman Syndrome Therapeutics) is an Internal Revenue Code Section 501(c)(3) nonprofit charity, exempt from federal taxation. Transparency is both a requirement and an obligation that is also vitally important to our members. 

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2021 Audited Financial Statements as well as a link to the FAST 2021 Federal Tax Return.  The FAST calendar year ended 2021 audited financials show total revenue of $6,327,514 and total expenses of $6,259,790. Additionally, there is $1,953,771 in non-operating losses recognized on FAST’s investment in GeneTx Biotherapeutics, LLC. Expenses of $6,259,790 include research funding in the amount of $3,910,364 and $1,607,858 in other program-related expenses. Fundraising expenses totaled $335,925, and general administrative expenses incurred by FAST in 2021 were $405,643.  $14,032,561 in net assets as well as $3,193,674 in grants payable were held at year-end, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see the FAST 2021 Audited Financials and FAST Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2020 Audited Financial Statements as well as a link to the FAST 2020 Federal Tax Return.  The FAST calendar year ended 2020 audited financials show total revenue of $4,167,109 and total expenses of $3,195,916. Additionally, there is $6,196,378 in non-operating gains recognized on FAST’s investment in GeneTx Biotherapeutics, LLC. Expenses of $3,195,916 include research funding in the amount of $2,401,977 and $421,618 in other program-related expenses. Fundraising expenses totaled $175,248, and general administrative expenses incurred by FAST in 2020 were $197,073.  $15,918,608 in net assets as well as $2,366,068 in grants payable were held at year-end, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. Notably, all compensation shown on Part VII of the FAST 990 is related to reportable compensation from our related organization, GeneTX Biotherapeutics, and properly classified in Column E. For detailed information, please see the FAST 2020 Audited Financials and  FAST Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2019 Audited Financial Statements as well as a link to the FAST 2019 Federal Tax Return.  The FAST calendar year ended 2019 audited financials show total revenue of $4,336,872 and total expenses of $5,128,132. Additionally, there is $1,968,564 in non-operating gains recognized on FAST’s investment in GeneTx Biotherapeutics, LLC. Expenses of $5,128,132 include research funding in the amount of $4,126,259 and $734,878 in other program-related expenses. Fundraising expenses totaled $183,057, and general administrative expenses incurred by FAST in 2019 were $83,938.  $8,751,037 in net assets as well as $3,197,375 in grants payable were held at year-end, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. Notably, all compensation shown on Part VII of the FAST 990 is related to reportable compensation from our related organization, GeneTX Biotherapeutics, and properly classified in Column E.   For detailed information, please see the FAST 2019 Audited Financials and  FAST Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2018 Audited Financial Statements as well as a link to the FAST 2018 Federal Tax Return.  The FAST calendar year ended 2018 audited financials show total revenue of $5,431,132 and total expenses of $3,104,807. Expenses of $3,104,807 include research funding in the amount of $2,260,991 and $414,253 in other program-related expenses.  Fundraising expenses totaled $203,437, and general administrative expenses incurred by FAST in 2018 were $226,126.  $7,573,733 in net assets as well as $1,174,132 in grants payable were held at year-end, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2018 Audited Financials and FAST Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2017 Audited Financial Statements as well as a link to the FAST 2017 Federal Tax Return.  The FAST calendar year ended 2017 audited financials show total revenue of $8,845,782 and total expenses of $5,739,913. Expenses of $5,739,913 include research funding in the amount of $5,218,272 and $232,586 in other program-related expenses.  Fundraising expenses totaled $191,049, and general administrative expenses incurred by FAST in 2017 were $98,006.  $5,247,408 in net assets as well as $2,462,895 in grants payable were held at year-end, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see  FAST 2017 Audited Financials and  FAST  Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2016 Audited Financial Statements as well as a link to the FAST 2016 Federal Tax Return.  The FAST calendar year ended 2016 audited financials show total revenue of $4,475,739 and total expenses of $3,529,159. Expenses of $3,529,159 include research funding in the amount of $3,039,187 and $63,381 in other program-related expenses.  Fundraising expenses totaled $313,486, and general administrative expenses incurred by FAST in 2016 were $113,105.  $2,141,539 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2016 Audited Financials and Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2015 Audited Financial Statements as well as a link to the FAST 2015 Federal Tax Return.  The FAST calendar year ended 2015 audited financials show total revenue of $1,121,173 and total expenses of $1,348,143. Expenses of $1,348,143 include research funding in the amount of $1,116,067 and $125,910 in other program-related expenses.  Fundraising expenses totaled $82,549, and general administrative expenses incurred by FAST in 2015 were $23,617.  $1,194,959 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2015 Audited Financials and Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2014 Audited Financial Statement as well as a link to the FAST 2014 Federal Tax Return.  The FAST calendar year ended 2014 audited financials show total revenue of $1,576,826 and total expenses of $1,256,386. Expenses of $1,256,386 include research funding in the amount of $1,042,667 and $112,293 in other program-related expenses.  Fundraising expenses totaled $78,121, and general administrative expenses incurred by FAST in 2014 were $23,305.  $1,571,929 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST.  For detailed information, please see FAST 2014 Audited Financials and Federal Tax Return.

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2013 Audited Financial Statement as well as a link to the FAST 2013 Federal Tax Return. The FAST calendar year ended 2013 audited financials show total revenue of $913,798 and total expenses of $979,548. Expenses of $979,548 include research funding in the amount of $808,469 and $63,544 in other program-related expenses. Total general administrative expenses incurred by FAST in 2013 were $24,509. $1,101,489 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2013 Audited Financials and Federal Tax Return 2013.

The FAST calendar year ended 2012 audited financials show total revenue of $955,052 and total expenses of $391,600. Expenses of $391,600 include research funding in the amount of $253,890 and $58,550 in other program-related expenses.  Total general administrative expenses incurred by FAST in 2012 were $34,920, which included $17,476 of general administrative expenses and temporarily restricted funds of $17,444 for family travel expenses incurred in the Minocycline Clinical Trial.  $1,167,239 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For further details visit the following hyperlinks; Audited Financial Statements 2012 & Federal Tax Return 2012.

The FAST calendar year ended 2011 audited financials show total revenue of $639,525 and total expenses of $207,400. Expenses of $207,400 include research funding in the amount of $125,110 and other program-related expenses of $41,561.  Total general administrative expenses incurred by FAST in 2011 were $6,621.  $603,787 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For further details visit the following hyperlinks; Audited Financial Statements 2011 & Federal Tax Return 2011.

FAST (Foundation for Angelman Syndrome Therapeutics) is an Internal Revenue Code Section 501(c)(3), a nonprofit charity, exempt from federal taxation. Transparency is both a requirement and an obligation that is also vitally important to our members.

View FAST’s W9 form.

View our Conflict of Interest & Whistleblower Policy

To keep up to date on the FAST funded research accelerating a cure, please share your email address:

THANK YOU for your interest!

Your donation will help us accelerate the therapeutics in our pipeline to secure a cure!

Donate Today
Donate Today